Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Evaluate the Efficacy and Safety of HAD-B1 for Dose-Finding in EGFR Mutation Positive and Locally Advanced or Metastatic NSCLC Subjects Who Need Afatinib Therapy

Afatinib is a target anticancer drug of the second-generation EGFR TKI type, showing an advantage in treatment effect compared to conventional chemotherapy. However, patients on EGFR-TKI drugs also usually progress after 9 to 13 months according to secondary resistance. HAD-B1 is composed of drugs t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Eun-Ju, Kwag, Eun-Bin, Park, Ji Hye, Park, So-Jung, Son, Ji-Woong, Yoon, Seong-Hun, Shin, Seong-Hun, Yoo, Hwa-Seung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381462/
https://www.ncbi.nlm.nih.gov/pubmed/34409891
http://dx.doi.org/10.1177/15347354211037917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381462/
https://www.ncbi.nlm.nih.gov/pubmed/34409891
http://dx.doi.org/10.1177/15347354211037917

Ejemplares similares